CT-guided laser therapy in resistant human tumors: phase I clinical trials.
Photodynamic therapy was performed on ten tumors in patients who did not respond to initial therapy and for whom no additional conventional therapy was available. A sensitizing agent (hematoporphyrin derivative [HpD]) was injected directly into each tumor under computed tomographic (CT) guidance to deliver high concentrations to the tumor and to minimize systemic toxicity. Three to 6 days after the injection, a clear Teflon sheath catheter was placed into the tumor under CT guidance. The tumor was exposed to red light (630-nm wavelength) through laser fiberoptics inserted in the sheath. The initial investigation confirmed the technical feasibility of CT-guided photodynamic therapy by means of intratumoral HpD injections and laser exposure through fiberoptics inserted in sheath catheters. The toxicity from a single treatment was minor, and the tumor response was encouraging.
D002404:Catheterization / Q000379:methods; D004341:Drug Evaluation; D005336:Fiber Optic Technology / Q000295:instrumentation; D006414:Hematoporphyrin Photoradiation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010778:Photochemotherapy; D014057:Tomography, X-Ray Computed